Inhibikase shareholders approve 5x authorized share increase to 500M and option repricing

Inhibikase Therapeutics, Inc.

Stockholders approved increase in authorized common shares from 100M to 500M; Certificate of Amendment filed Jan 3, 2025.
Approved elimination of 66 2/3% supermajority vote requirement for amendments to Article IV.
Approved 27,453,993 share increase in 2020 Equity Incentive Plan reserve.
Approved repricing of certain outstanding stock options; all proposals passed with >97% of votes cast.
Vote results: share increase – 62.5M for, 377K against; no broker non-votes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Inhibikase Therapeutics, Inc.: Stockholders approved amendments to the Certificate of Incorporation to increase authorized common shares from 100,000,000 to 500,000,000 and eliminate the supermajority vote requirement for amendments to Article IV Section 1 (effective 2025-01-03).

Change: charter amendment
Effective: 2025-01-03

Exact text from the filing

A Special Meeting of Stockholders (the “ Special Meeting ”) of Inhibikase Therapeutics, Inc. (the “ Company ”) was held on January 3, 2025. As further described in Item 5.07 to this Current Report on Form 8-K, at the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “ Certificate of Amendment ”) to increase the number of the Company’s authorized shares of common stock from 100,000,000 shares to 500,000,000 shares and eliminate the 66 2/3% affirmative vote requirement for amendments to Section 1 of Article IV thereof, as described in the Company’s definitive proxy statement filed on November 18, 2024 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The Certificate of Amendment was previously approved by the Company’s board of directors, subject to approval by the Company’s stockholders. On January 3, 2025, the Company filed the Certif

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-001787

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.